Healthcare Tech Outlook
About Healthcare Tech Outlook
Healthcare Tech Outlook is a healthcare technology print magazine that provides a knowledge network for healthcare industry experts. It highlights the latest healthcare technology trends by bringing forth the ideas and values of healthcare industry leaders, and healthcare technology solutions to the current issues faced in the healthcare arena.
Missing: Healthcare Tech Outlook's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Healthcare Tech Outlook's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Healthcare Tech Outlook News
May 17, 2023
Southlake Texas, UNITED STATES Southlake, Texas, May 17, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announces it has been recognized by Healthcare Tech Outlook Magazine as a 2023 Top healthcare artificial intelligence solutions provider , highlighting the Company’s MyoVista device. “We are honored to be recognized as one of the Healthcare Tech Outlook’s Top AI companies,” said Andrew Simpson, CEO. “We believe the evidence is now indisputable that applying artificial intelligence to the ECG will allow it to detect a much wider range of heart disease which offers the meaningful prospect of early detection and screening. Last week we announced the completion of patient enrollment for our FDA pivotal study and look forward to making an FDA submission later in the year, assuming positive results. Today, despite its limitations in detecting most forms of heart disease, millions of ECGs are performed every week. Our ultimate objective is to become a fixture in frontline healthcare to help physicians make better and earlier referral decisions for at risk patients.” Healthcare Tech Outlook was founded to bring forth the complete picture of how the healthcare landscape can be enhanced and brought to new heights through the adoption of technology. In announcing the “ Top 10 Artificial Intelligence Solutions Providers, ” Healthcare Tech Outlook stated, “Artificial Intelligence (AI) is at the forefront of healthcare innovation… healthcare expenditure on AI software is predicted to increase by 40% in 2023.” About HeartSciences Heart Test Laboratories, Inc. d/b/a HeartSciences is a next-generation, AI electrocardiogram (AI ECG) company focused on using AI to transform the ECG (also known as the EKG) to save lives through earlier detection of heart disease. Millions of ECGs are performed every week and AI is creating a new era of opportunity for the ECG with recent AI ECG applications described as “some of the most significant advances in electrocardiography since its inception1.” The Company’s objective is to become a fixture in front-line healthcare settings to help physicians make better and earlier referral decisions for at-risk patients. For more information, please visit: https://www.heartsciences.com . Twitter: @HeartSciences 1 - Khurram Nasir, MD, MPH, MSC,et. al., Journal of American College of Cardiology Editorial Comment Volume 76 Number 8 2020. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences’ beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences’ filings with the U.S. Securities and Exchange Commission at www.sec.gov . Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements. For investor and media inquiries, please contact: Investor Relations:
Healthcare Tech Outlook Frequently Asked Questions (FAQ)
Where is Healthcare Tech Outlook's headquarters?
Healthcare Tech Outlook's headquarters is located at Austin.
Who are Healthcare Tech Outlook's competitors?
Competitors of Healthcare Tech Outlook include Healthcare Business Insights and 4 more.
Compare Healthcare Tech Outlook to Competitors
Blaze Systems is a provider of total LIMS software solutions for the laboratory marketplace.
Kryosphere provides customized biorepository, logistical, and clinical sample management services to companies with a critical biospecimen component. Kryosphere delivers secure, scalable solutions to customers ranging from small, emerging entities to large corporations worldwide.
J. Lamarck is a company that offers advisory services to private individuals, companies and pension funds who want to invest in the biotechnology sector.nThe company offers a high quality service and its analyst provide professional assistance to people who want to diversify a part of their portfolio in this emerging industry. Because of the nature of biotechnology investments, the company believe it is important that users work with specialists to define their portfolio strategy. Generally, specialists do things better.nOver the next few years the company will be witness of astonishing progress in health care and medicine, the company will be able to fight and cure diseases like AIDS and cancer finally. The company will also find solutions to clean up the environment and new crops that don't need pesticide. These new products will obviously boost the visibility of the companies that were at the beginning of this process on the stock market and consequently create great opportunity for it's shareholders.nJ. Lamarck wants to be their partner in this great venture.
Punjab Biotechnology Incubator (PBTI) welcomes users to its state-of-the- art Agri & Food Testing Laboratory set up at SAS Nagar (Mohali), the hub of Biotechnology and Information Technology in Punjab. PBTI is a State Govt. Undertaking registered as a "˜Society for Biotechnology Incubator' under the Society Registration Act 1961 and is professionally governed by Governing Council of the Society under the chairmanship of Chief Secretary, Govt. of Punjab. The day to day affairs are managed by Chief Executive Officer, supported by technical professionals of high caliber.
Laureate Pharma, Inc. is a full service contract manufacturing organization(CMO) providing development and cGMP manufacturing services in the company's FDA registered facilities in Princeton, New Jersey. The company is dedicated to supporting the development and commercialization of biopharmaceutical, drug and diagnostic products for pharmaceutical, diagnostic and biotech companies.The company aims to provide a range of product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The company's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply.The company view the company's customers as partners and provide them with flexible solutions that reduce time to clinic and market. Focused on operational excellence, the company's highly experienced staff works with the company's customers to improve the quality of their products and processes.The company value the company's customers, stakeholders and associates. Therefore, the company measure the company's success by meeting the company's customers' needs, generating results in terms of quality, timeliness and on budget performance, as well as fostering an environment of trust, growth and diversity for the company's team.
Critical Biologics Corporation (CBC), based in Cambridge, MA, is a small biotechnology company committed to making available products to address the many unmet medical needs in Critical Care Medicine. The company believe that the traditional commercial approach of targeting a single facet of a therapydrug, device, diagnostic, or monitor ignores the fact that often these modalities are employed together by Intensivists to treat the increasing complex diseases of their patients.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.